Payers

Corxel’s oral GLP-1 trial adds momentum. The real question is who these drugs will reach

Deep learning uncovers a new ECG biomarker for sudden cardiac death

Half of CKM patients go untreated and most fail control

For Cancer That Reaches the CNS, a Payer Opens a Door

Sleep is now cardiovascular prevention. Health systems still treat it like lifestyle advice

The GLP-1 boom still needs exercise policy

Europe Opens Another Lung Cancer Door to China-Origin Immunotherapy

In Australia, Cancer Medicine Delays Cost More Than Time

Pharmacists are becoming the front door for cardiometabolic care. Policy is still treating them like the back office
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
